The renin-angiotensin system may be involved in the development of experimental renal hypertension (1) and some forms of hypertension in humans (2) . According to the most widely accepted hypothesis (3) , angiotensinogen (renin substrate) is converted to angiotensin I, a decapeptide, by renin during renal ischemia (4) or reduced mean arterial blood pressure (5) . The octapeptide, angiotensin II, is formed from angiotensin I by the converting enzyme in plasma. Angiotensin II, a potent pressor agent, has been suggested to increase renal blood flow (RBF) during renal ischemia secondarily to an increased renal perfusion pressure (6, 7) . This hypothesis fails to account for the marked renal vasoconstrictor property of angiotensin II (8) . The increase in renal vascular resistance (RVR) elicited by angiotensin has been shown to be the largest of ary vascular bed (9, 10) . Furthermore, renal ischemia has been challenged as a stimulus activating the renin-angiotensin system (11, 12) .
The present study was undertaken to define the action of angiotensin II during renal ischemia. Abolition of the renal vasoconstrictor activity of angiotensin II was found during renal ischemia. Thus, the pressor effect of angiotensin would promote an increased RBF to an ischemic kidney. The enhanced RBF then may obscure the initial ischemic stimulus. In addition, this study describes the development of altered reactivity of the renal vasculature to the vasoconstrictor proper-* Submitted for publication June 2, 1964 ; accepted August 17, 1964. Abstracts of this article appeared in J. clin. Invest. ties of angiotensin II that may occur in the absence of renal ischemia.
Methods
Twenty-six mongrel dogs weighing 19 to 32 kg were anesthetized with morphine sulfate (2 mg per kg, subcutaneously) and chloralose (70 mg per kg, intravenously). The trachea was cannulated, and the lungs were ventilated by a Starling ideal pump. Heparin 1 (200 to 400 international U per kg) was administered intravenously as the anticoagulant.
A Sanborn polyviso recorded the following: 1) Mean arterial pressure was recorded by a Statham transducer from a catheter inserted into the right femoral artery. In three experiments aortic blood pressures were recorded proximal and distal to an aortic constriction placed just above the renal arteries to permit determination of renal vascular resistances in the ischemic kidney.
2) The blood flow of one kidney was measured in 22 experiments. In four experiments both RBF's were measured simultaneously. The venous outflows of the kidneys were measured. The renal vein was cannulated; renal arterial flow was interrupted for no more than 2 minutes during renal vein cannulation. Venous cannulation was selected, rather than arterial, for it permits preservation of renal innervation. The effluent was passed through a rotameter (200 ml) of Shipley-Wilson, which was placed below the renal vein. After passage through the rotameter, the blood emptied into a reservoir. The blood was then returned to the femoral vein of the animal by a Sigmamotor pump that was automatically activated by a predetermined level of blood in the reservoir. The volume of blood in the reservoir that was maintained throughout the experiment was 40 ml. The entire recording system contained no more than 120 ml of blood, representing about 6%o of the dog's blood volume. An equal volume of plasma expander (6%c gelatin solution) was administered in the beginning of the experiment.
Angiotensin II 2 (0.05 to 2.5 Ag per kg), atropine sulfate (0.2 mg to 2 mg per kg), tetraethylammonium chloride (TEAC) (10 mg per kg), and epinephrine bitartrate and levarterenol bitartrate (0.4 to 2.0 lcg per kg) were 1 Panheprin, Abbott Laboratories, North Chicago, Ill. 2 Hypertensin, Ciba Pharmaceutical Co., Summit, N. J. was tightened without displacing the vessel from its bed; care was taken to avoid traction upon the vessel.
In four experiments acute denervation of the kidney was accomplished by careful dissection of the structures as they traversed the renal hilum. Renal arterial transection was then carried out. The kidney was then perfused with blood from the carotid artery through a cannula inserted into the distal end of the sectioned renal artery. This procedure required 3 Vascular resistances were calculated from the maximal change in flow and the simultaneous blood pressure elicited by the stimulus. Statistical analyses were made on paired analyses of control and experimental values of the maximal change in RBF and the associated blood pressure after application of the stimulus. The coefficient of correlation was calculated for the control blood flow of the ischemic kidneys and the percentage increase in RBF elicited by angiotensin (13) .
Results

A. Effect of awgiotensin II on the nonischemic renal vasculature
After administration of angiotensin II intravenously, the RVR was increased by 150% of control values (Table I) . Within the range of the dosage employed (0.05 to 2.5 ug per kg, intravenously, or 0.01 to 0.5 pxg per kg, intra-arterially), there was no constant relationship between the magnitude of the changes in the RVR and the dose of angiotensin II. With the appearance of reduced vascular reactivity, the threshold dose of angiotensin II necessary to constrict the renal vessels was elevated.
B. Reduced vascular response of the nonischentic renal vasculature to angiotensin II Altered renal vascular reactivity, to angiotensin II, which generally followed several periods of renal ischemia, was noted frequently. In Figure  1 , after release of the renal arterial constriction, the RBF response to intra-aortic administration of angiotensin II was markedly diminished.
The appearance of reduced vascular reactivity to angiotensin II was accelerated by periods of renal ischemia. (Table I ). Figure 3 illustrates the almost complete restoration of RBF of an ischemic kidney to control levels after an intravenous injection of angiotensin II. Ninety seconds after release of the constriction, the same dose of angiotensin II that produced an increase in RBF now elicited a sharp reduction in RBF (Figure 3 ). ,ug per kg) produced a further reduction of RBF during renal ischemia ( Figure 1 , Table I ).
2) Role of a reduction in renal blood flow. In order to evaluate the effect of a reduction in RBF on angiotensin activity, hemorrhagic hypotension and levarterenol infusions were employed in two experiments each. Hemorrhagic hypotension (15 to 20 ml per kg) and levarterenol infusion (2 pug per kg per minute) caused reductions of RBF similar to those induced by renal arterial constriction (30 to 70%). Administration of angiotensin II during these periods of reduced RBF caused a further reduction of RBF.
3) Two renal blood flows measured simultaneously (Table II) . In four experiments the blood flows of each kidney were measured simultaneously. Constriction of the abdominal aorta between the origin of the renal arteries resulted in Figure   4 and Table II ). Figure 1 ). Intravenous administration of angiotensin II, which elicited a modest pressor response, produced an increased RBF (Figure 1 order to explore the relationship between the sympathetic nervous system and angiotensin, acute renal denervation was carried out in four experiments (Table IV) . Acute renal denervation resulted in abolition of the renal vasoconstriction elicited by intravenous administration of angiotensin II ( Figure 5 ). Therefore, after denervation of the kidney, the response of the RBF to angiotensin II in the nonischemic state resembled the response obtained during renal ischemia.
Discussion
The essential observation made in these experiments, alteration of the renal vasoconstrictor action of angiotensin II during renal ischemia, suggests a homeostatic role for angiotensin II that would increase the blood flow to an ischemic kidney. The previously described (9, 10) marked sensitivity of the renal vascular bed to the vasoconstrictor effect of angiotensin II was inconsistent with the hypothesis (6, 7) that angiotensin II increased RBF in an ischemic kidney by raising renal perfusion pressure.
If the initial event in the production of renal hypertension were renal ischemia, the ischemia could be obscured by the homeostatic mechanism invoked by it (Figure 3) . Vasoconstriction was demonstrated in the nonischemic kidney simultaneously with an increased RBF in the contralateral ischemic kidney (Figure 4) . A redistribution of regional blood flow would favor the ischemic kidney due to the increased renal perfusion pressure coupled to the loss of angiotensininduced vasoconstriction in the ischemic kidney.
The data presented may reconcile the proponents of renal ischemia as the sine qua non of hypertension (4) of renal origin and those who maintain that there is no constant relationship between nephrogenic hypertension and renal ischemia (12) . Thus, the observations of an inconstant reduction in RBF in the hypertension of coarctation of the aorta (14) , the hypertension associated with renal arterial disease (15) , and experimental renal hypertension (11) Renal ischemia facilitated the rapid development of altered reactivity of the renal bed to angiotensin II. The reduced vascular reactivity progressed at times to abolition of the renal vasoconstrictor effect of angiotensin II in the absence of renal ischemia (Figure 2 ). Tachyphylaxis to the vascular effects of small to moderate amounts of angiotensin II administered by prolonged intravenous infusion (16) or repeated injections (17) in unanesthetized dogs has not been demonstrated. However, tachyphylaxis expressed by a change in the pressor response (17) or the glomerular filtration rate and renal plasma flow (18) to angiotensin II in high doses has been reported. In secondary hyperaldosteronism, a tachyphylaxis to angiotensin II, even in small amounts, has been suggested to explain the reduced vascular sensitivity to injected angiotensin II (19) . During renal ischemia the elaboration of angiotensin II in the ischemic kidney may induce a local vascular tachyphylaxis. The development of reduced renal vascular reactivity to angiotensin II may uncover other sites of activity of angiotensin II, namely, a direct tubular effect of angiotensin II on sodium absorption (20) .
The present experimental design did not permit the complete definition of the factors responsible for the loss of the renal vascular response to angiotensin II during renal ischemia. Several possible explanations, however, may be considered likely, since some of the elements in this experimental preparation that affect the renal vascular response have been separated. The first to be considered is the role of an increased perfusion pressure associated with a local (ischemic kidney's) loss of the renal vascular effect of angiotensin II. This explanation is supported by the essentially unchanged RVR elicited in the ischemic kidney by angiotensin II in the three experiments in which this measurement was made. This would suggest that the increased RBF elicited by angiotensin II during renal ischemia followed passively the increased perfusion pressure. There are known plasma, red cell, and kidney angiotensinases of high specificity (21, 22 ) that may inactivate angiotensin II in the ischemic kidney. A local renal vascular tachyphylaxis may accomplish the same effect, so that the pressor response to angiotensin II is unaccompanied by vasoconstriction in the ischemic kidney. Intra-aortic administration of angiotensin II at the level of the renal arteries failed to dissociate the increase in RBF from the pressor response to angiotensin II administration (Figure 1 ). There was no significant relationship (p > 0.05) between the pressor response and the degree of increase in blood flow induced by angiotensin II to the ischemic kidney. This would suggest that factors in addition to an increase in blood pressure determined the increase in blood flow to the ischemic kidney in re- sponse to angiotensin II. Thus, there was a significant relationship between the degree of renal ischemia and the percentage increase of RBF elicited by angiotensin II (Figure 6 , coefficient of correlation = -0.59, p < 0.01). Finally, the relationship of angiotensin II to autonomic nervous activity may determine in part the reversal of the effect of angiotensin II upon the vasculature of the ischemic kidney. In isolated smooth muscle preparations, the activity of angiotensin II is partially dependent upon the release of acetylcholine (23) . In the present preparation, however, atropine did not reduce the effect of angiotensin II on the renal vasculature. The vasoconstrictor activity of angiotensin II has been related partially to the integrity of sympathetic nervous-activity (24, 25) . In addition, the vasoconstrictor effect of angiotensin II has been reported to be in part central nervous system dependent (26, 27) . Acute denervation of the kidney yielded the most unexpected results in the nonischemic kidney, namely, an elimination of the renal vasoconstrictor response to angiotensin II administered intravenously ( Figure 5 , Table IV) . Thus, the vasculature of the denervated kidney in the nonischemic state behaved as that of the ischemic kidney in its response to angiotensin II.
A final explanation of the altered vascular response of the ischemic kidney to angiotensin II must await a more complete elaboration of the mode of action of vasoactive polypeptides, the relation of these substances to the autonomic nervous system, and a fuller definition of the angiotensinase system. 
